Search
Venetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalVenetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetocl...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsGestrinone
go.drugbank.com/drugs/DB11619ApprovedGestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and is used primarily in the treatmen...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesOpicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigationalOpicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine. Many patients with Parkinson’...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, P-glycoprotein substratesAmifampridine
go.drugbank.com/drugs/DB11640ApprovedPatients with LEMS develop serum antibodies against presynaptic P/Q-type voltage-gated calcium channels, leading to decreased presynaptic calcium levels and reduced quantal release of acetylcholine, which
Tropisetron
go.drugbank.com/drugs/DB11699ApprovedInvestigationalWithdrawnTropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radioth...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesAmenamevir
go.drugbank.com/drugs/DB11701InvestigationalAmenamevir has been used in trials studying the treatment of Herpes Zoster, Herpes Simplex, Herpes Genitalis, and Safety of Amenamevir.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 SubstratesLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cho...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsLasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigationalLasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. It was also approved by the European Commission on August 17, 2022. Traditionally, the t...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawnRifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent comp...
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitors